| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | ASCO26: In vivo oncology approaches continue to show promise | ||
| Di | ASCO26: Blood cancer readouts take centre stage | ||
| Di | BMS secures FDA acceptance for Camzyos sNDA | ||
| Di | Servier to acquire Edgewise's muscular dystrophy business for $2.65bn | ||
| Mo | ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise | ||
| Mo | ASCO26: key readouts in lung cancer | ||
| Mo | ASCO26: BMS and J&J debut shining multiple myeloma data | ||
| Mo | Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide | ||
| Mo | FDA approves AstraZeneca's Imfinzi-BCG combination for NMIBC therapy | ||
| Fr | GSK's Nucala secures NICE COPD endorsement | ||
| Fr | Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal | ||
| Fr | FDA grants priority review for Sanofi's venglustat NDA | ||
| Do | FDA oncology roundup: AbbVie's rare cancer approval, AstraZeneca in breast cancer limbo | ||
| 27.05. | California startup Protuoso raises $9.5m for "mix-and-match" drug platform | ||
| 27.05. | Kardigan targets IPO to support cardiology pipeline progression | ||
| 27.05. | Autobahn's elunetirom receives FDA fast track designation to treat adjunctive bipolar | ||
| 27.05. | SK bioscience and VECOL partner on Colombia vaccine manufacturing initiative | ||
| 26.05. | EMA recommends approvals for both oral and high-dose pen of Wegovy | ||
| 26.05. | Eli Lilly to buy trio of vaccine developers in $3.8bn outlay | ||
| 26.05. | University of Edinburgh develops cell therapy for liver disease | ||
| 26.05. | Pierre Fabre's Braftovi gains CHMP positive opinion for mCRC | ||
| 25.05. | AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC | ||
| 22.05. | CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati | ||
| 22.05. | European STI cases reach record high amid testing and prevention gaps | ||
| 22.05. | Gilead Sciences acquires Tubulis for $5bn |